Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a ...

A mobile prostate cancer screening program proved feasible for men in underserved neighborhoods and led to a high rate of ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a prostate cancer poster session. Dr. Ida Sonni presented a study evaluating the diagnostic performance of 18 ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

The primary study objective was to evaluate the prognostic value of post-therapeutic SPECT by RECIP 1.0 for overall survival.

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy (MDT) in addition to systemic treatment, a meta-analysis of recent studies ...

Testosterone therapy after prostate cancer surgery does not appear to increase biochemical recurrence (BCR) risk in patients with low-risk disease, investigators report.

The CDC confirmed isolation of an mpox variant case in New York, WHO criticized the US for pausing foreign health aid, ...